NCT00313248 - Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

November 30, 2008

Conditions

Breast Neoplasm

Interventions

DRUG

Sagopilone (ZK 219477)

All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.

DRUG

Sagopilone (ZK 219477)

Patients will receive 22mg/m2 as intravenous infusion.

Trial Locations (25)

10021

New York

13210

Syracuse

20007

Washington D.C.

21204

Baltimore

32114

Daytona Beach

35233

Birmingham

47150

New Albany

55455

Minneapolis

62526

Decatur

71913

Hot Springs

77030

Houston

78207

San Antonio

80010

Aurora

85724

Tucson

92262

Palm Springs

93309

Bakersfield

97239

Portland

98405

Tacoma

99508

Anchorage

07039

Livingston

15213-3180

Pittsburgh

M4N 3M5

Toronto

J4V 2H1

Greenfield Park

H3T 1E2

Montreal

G1S 4L8

Québec